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Pain remains a significant problem for patients hospitalized in intensive care units (ICUs). As research has shown, for
some of these patients pain might even persist after discharge and become chronic. Exposure to intense pain and
stress during medical and nursing procedures could be a risk factor that contributes to the transition from acute to
chronic pain, which is a major disruption of the pain neurological system. New evidence suggests that physiological
alterations contributing to chronic pain states take place both in the peripheral and central nervous systems. The
purpose of this paper is to: 1) review cutting-edge theories regarding pain and mechanisms that underlie the
transition from acute to chronic pain, such as increases in membrane excitability of peripheral and central nerve
fibers, synaptic plasticity, and loss of the function of descending inhibitory pain fibers; 2) provide information on the
association between the immune system and pain and its crucial contribution to development of chronic pain
syndromes, and 3) discuss mechanisms at brain levels in the nervous system and their contribution to affective (i.e.,
emotional) states associated with chronic pain conditions. Finally, we will offer suggestions for ICU clinical
interventions to attempt to prevent the transition from acute to chronic pain.
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Most, if not all, patients in intensive care units (ICUs)
will experience pain at some point during their ICU stay
related to their injury, surgery, burns, or comorbidities,
such as cancer,and/or from the myriad procedures per-
formed for diagnostic or treatment purposes [1-4]. In-
deed, even medical patients experience substantial pain
at rest [5]. Despite increased attention to assessment
and pain management,pain remains a significant prob-
lem for ICU patients [1,6-8].
Unrelieved pain in adult ICU patients is far from be-
nign. Medical and surgical ICU patients who recalled
pain and other traumatic situations while in the ICU
(27% of 80 patients) had a higher incidence of chronic
pain and posttraumatic stress disorder symptoms than
did a comparative group of ICU patients [9]. Indeed, con-
current or past pain may be the greatest risk factor for
development of chronic pain [4,10]. Despite clinical con-
cerns about the contribution of ICU hospitalization to* Correspondence: mkiranou@yahoo.com
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reproduction in any medium, provided the origdevelopment of chronic pain, a systematic review of the
literature on quality of life (QOL) after hospitalization in
an ICU concluded that chronic pain in ICU survivors did
not differ from a matched normal population [11], except
in patients with acute respiratory distress syndrome
(ARDS) [12].
Nevertheless, recent findings from studies in various
ICU patient populations as well as with longer follow-up
periods are in keeping with the findings for chronic pain
in patients with ARDS. Patients discharged from a
medical-surgical ICU reported higher bodily pain at
12 months after hospitalization compared with 3 months
[13]. For patients with burns hospitalized in an ICU, the
majority of responders (79% of patients) suffered from
moderate to severe pain 1 year after the injury [14]. Fur-
thermore, a group of German researchers found highly
significant differences in the pain intensity and pain
interference between survivors of severe sepsis com-
pared with a healthy German population [15]. However,
others have not confirmed these findings in ICU survi-
vors of sepsis in the Netherlands [16].
When the follow-up of the patients after hospitalization
in an ICU was even longer, such as 2 years after major. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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or extreme problems in usual activities: 56% had pain, and
56% had mobility problems [17]. Similarly, patients hospi-
talized in a medical-surgical ICU had higher bodily pain
reports 5 years after discharge compared with 3 months
[18]. Importantly, according to the findings of a recent
study with a mean follow-up of 8 (range, 6–11) years,
nearly half of all patients hospitalized in an ICU for all
surgical classifications combined still had problems with
cognition (43%), mobility (52%), and pain/discomfort
(57%) [19].
Despite methodological problems with these studies,
mainly small sample of patients, no homogeneity of pain
measures, and high mortality rate or loss to follow-up,
the observations for severe functional limitations com-
bined with high reports of pain even years after ICU dis-
charge grant further exploration. Important questions to
ask are: Why does acute pain transition into a chronic
pain state in some patients? Might medical and/or nurs-
ing procedures performed during the ICU stay, or other
painful stimuli experienced by patients in ICUs, be con-
tributing factors to the neurological mechanism of the
transition?
Today, we know more about the physiological mechan-
isms of acute pain as well as mechanisms of acute-to-
chronic pain. Therefore, the purpose of this paper is to
emphasize the risk that exists for ICU patients and others
in developing chronic pain as a result of an acute pain ex-
perience. To do so, we will: 1) review cutting-edge theories
regarding pain and mechanisms that underlie the transi-
tion from acute to chronic pain, such as increases in
membrane excitability of peripheral and central nerve
fibers, synaptic plasticity, and loss of the function of des-
cending inhibitory pain fibers; 2) provide information on
the association between the immune system and pain and
its crucial contribution to development of chronic pain
syndromes; and 3) discuss mechanisms at supraspinal
levels in the nervous system and their contribution to
affective (i.e., emotional) states associated with chronic
pain conditions. As we address these three issues, we will
be able to offer suggestions for clinical interventions to at-
tempt to prevent the transition from acute to chronic
pain.
Terminology used to describe the phases of the transition
from acute to chronic pain
The International Association for the Study of Pain
(IASP) describes pain as “an unpleasant sensory and
emotional experience associated with actual or potential
tissue damage, or described in terms of such damage”
[20]. Acute pain can arise from cutaneous (i.e., from the
skin), deep somatic (i.e., from muscle, bone) or visceral
structures (i.e., from organs within the chest and abdo-
men) [21]. When unexpected exposure to potentiallyharmful stimuli occurs, pain manifests as an automatic
(reflex) withdrawal response along with a motivational
reaction, most frequently a feeling of unpleasantness
(i.e., a negative affect) [22]. The sensory process of
detecting the “actual or potential tissue damage” is called
nociception and clinically manifests as hypersensitivity
to mechanical (e.g., pressure applied to an abdominal in-
cision during coughing), thermal (e.g., heat from burns),
or chemical stimuli (e.g., when inflammatory substances
are released during an injury). (See Table 1 for defini-
tions of hypersensitivity and other terms used in this
review.) The hypersensitivity at the site of the injury that
is associated with acute pain motivates the patient to
avoid further damage [23,24] and, thus, is protective of
tissues and the organism [25]. Yet, this hypersensitivity
may cause delayed mobilization if the ICU patient is in
too much pain [26]. In the context of injury (e.g.,
trauma, surgery), acute pain might persist for a few
hours or days or even for up to several months and is
still considered acute [27].
Peripheral sensitization is usually the result of expos-
ure of nociceptors (i.e., receptors that respond to a nox-
ious stimulus) to inflammatory products and mediators
of tissue injury. This subsequently contributes to reduc-
tions in nerve thresholds at nociceptive terminals,
increases in sensitivity, and amplification of the excit-
ability of the peripheral afferent nerve fibers [32].
Whereas this action can last for an extended period of
time, it is not permanent [34]. Under normal circum-
stances, peripheral hypersensitivity returns to normal
when inflammation subsides or the source of the injury
is removed. Consider, for example, the sensitivity of a
surgical incision that decreases over a matter of days.
However, in certain instances, pain can exceed the aver-
age period of healing, cease serving any apparent protective
function, and become chronic (i.e., after 2 to 3 months)
[34,35]. In these cases, peripheral hypersensitivity does not
return to normal. On the contrary, it indirectly contributes
to the initiation of central sensitization; i.e., sensitization of
the spinal cord nerves. During central sensitization,
nociceptive-specific neurons may progressively increase
their response to repeated nonpainful stimuli, develop
spontaneous activity, and increase the area of the body that
is involved with the pain [36]. The hyperalgesia of central
sensitization usually develops as part of ongoing pathology
(i.e., damage to peripheral or central nerve fibers, cancer,
rheumatoid arthritis) and is considered maladaptive. Fur-
thermore, hyperalgesia can be induced by opioid adminis-
tration and/or interruption, although this phenomenon is
not well understood yet [37]. Judicious treatment of pain
in the ICU may help to preempt development of central
sensitization. This is important, because once this type of
sensitization occurs for prolonged periods, it can be main-
tained by lower or different kind of inputs to the central
Table 1 Explanation of pain terminology
Acute pain Intensely discomforting, distressful, or agonizing sensation associated with trauma or disease,
with well-defined location, character, and timing [20]). Year introduced: 2012.
Allodynia Pain due to a stimulus that does not normally provoke pain [20].
Central sensitization Increased responsiveness of nociceptive neurons in the central nervous system to their normal
or subthreshold afferent input [20].
Chronic pain Pain that continues or recurs over a prolonged period, caused by various diseases or abnormal conditions [28].
Hyperalgesia Increased pain from a stimulus that normally provokes pain [20].
Hypersensitivity
or hyperesthesia
Increased sensitivity to stimulation, excluding the senses [20].
Long-term potentiation
(LTP)
A long-lasting strengthening of the response of a postsynaptic nerve cell to stimulation
across the synapse that occurs with repeated stimulation and is thought to be related to
learning and long-term memory [29].
Modulation The inhibition or facilitation of pain [30].
Neuropathic pain Pain caused by a lesion or disease of the somatosensory nervous system [20].
Pain affect Feeling or emotion related to pain, especially as manifested by facial expression or body language [31].
Pain sensation An unpleasant sensory experience associated with actual or potential tissue damage,
or described in terms of such damage [20].
Peripheral sensitization Increased responsiveness and reduced threshold of nociceptive neurons in the periphery to the
stimulation of their receptive fields [32].
Sensitization An increased response to stimulation that is mediated by amplification of signaling [32].
Supraspinal Situated above the vertebral column [31].
Synaptic plasticity The ability of the connection, or synapse, between two neurons to change in strength in response to use or
disuse of transmission over synaptic pathways [33].
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pain, or pain caused by damage to peripheral or central
nerve fibers themselves.Mechanisms involved in the transition from acute to
chronic pain increases in membrane excitability of
peripheral nerve fibers
Peripheral neurons that respond to noxious stimuli and
serve to detect potentially harmful thermal, mechanical,
or chemical stimuli are called nociceptors [38]. There
are two main types of nociceptors: medium-diameter
myelinated Aδ afferents that mediate acute pain that
occurs quickly and is well localized; and small-diameter
unmyelinated C fibers that initiate a slightly delayed and
more diffuse pain [39].
Increases in the membrane excitability of peripheral
nociceptors most commonly result from inflammation-
associated changes in the chemical environment of the
nerve fiber [40]. Activated nociceptors as well as non-
neuronal cells that reside within, or infiltrate into, the
injured area (e.g., mast cells, macrophages, platelets,
endothelial cells) release a variety of molecules, including
neuropeptides [e.g., substance P, calcitonin gene-related
peptide (CGRP), bradykinin], neutrophins, cytokines, and
eicosanoids or related lipids (e.g., prostaglandins, throm-
boxanes, and leukotrienes). These substances bind to
receptors on peripheral nociceptive terminals, which
leads to heightened excitability of the nerve fiber.In addition, the release of numerous cytokines, includ-
ing interleukin-1β (IL-1β), IL-6, and tumor necrosis fac-
tor α (TNF-α) [41], activates the immune system which,
in turn, may affect neuronal function and increase pain
responses. As evidence of this, administration of a proin-
flammatory cytokine antagonist immediately after per-
ipheral nerve injury or inflammation reduces pain
responses [42-45]. The number of macrophages that are
present at a site of injury has directly correlated with the
severity of neuropathic pain [46,47]. ICU clinicians can
attempt to decrease the effects of these inflammatory
mediators of pain by considering the use of anti-
inflammatory agents, such as indomethacin, as an ad-
junctive therapy to other pain medications if the patient
has no contraindications to their use [48]. Contradictions
can include renal insufficiency, active peptic ulcer dis-
ease, and coagulation problems [49].
Increases in membrane excitability of dorsal root ganglia
Nociceptors have peripheral axonal branches that convey
information from the periphery to ganglia outside the
spinal cord and central axonal branches that convey in-
formation from the ganglia to the spinal cord. The cell
bodies of peripheral nociceptors are located in dorsal
root ganglia (DRG) for stimuli originating in the body
and in the trigeminal ganglion for stimuli from the face
and mouth. Following nerve injury and in the setting of
inflammation, primary sensory neurons become hyper-
excitable, altering the organization of DRG neurons [50].
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immune-like cells (e.g., endothelial cells, dendritic cells,
glially derived) that exist in close proximity to each DRG
neuronal cell body [51]. In response to peripheral nerve
damage and/or inflammation, the above nonneuronal
cells, as well as immune cells, drawn into the DRG from
the circulation, release proinflammatory cytokines and
growth factors [52]. These responses contribute to the
upregulation of cytokine receptors in DRG neurons [53-
55], which leads to the release of substance P [56] and
calcitonin gene-related peptide [57], which are pain-
generating substances. Gradually, these events lead to
DRG membrane depolarizations, and nociceptors start
firing nociceptive signals from the DRG to the spinal
cord at increased frequency [34]. Preventing this inflam-
matory cascade may keep these normally quiet cells
from firing [58].
Synaptic plasticity in the spinal cord
The outer area within spinal cord consists of white matter,
and the inner area is composed of gray matter. These areas
comprise a busy milieu of nerve fiber transmission. The
white matter contains ascending and descending neuronal
tracts. The grey matter contains ten different layers, known
as the Rexed laminae, on the basis of the characteristics of
their neurons. The dorsal horn (posterior), where primary
nociceptive afferent nerve fibers project, contains laminae I
to VI, whereas the ventral horn (anterior), comprising the
motor neurons, contains laminae VII to IX. Lamina X sur-
rounds the central canal (Figure 1).
Neurons in lamina I receive direct synaptic input from
Aδ and C nociceptive fibers and respond exclusively to
nociceptive stimulation. Lamina II, also called the sub-
stantia gelatinosa, is made up almost exclusively of inter-
neurons (both excitatory and inhibitory). Some of theseFigure 1 Rexed's laminae in a cross-section of the spinal cord at appr
permission.interneurons respond only to nociceptive inputs,
whereas others respond to both nociceptive and non-
nociceptive stimuli [38]. Lamina III and IV contain neu-
rons that receive input from Aβ fibers that respond pre-
dominantly to nonnoxious stimuli (e.g., touch).
Importantly, lamina V contains primarily neurons that
respond to a wide range of stimulus intensities as well as
a combination of inputs (i.e., nociceptive and nonnoci-
ceptive, from skin, muscle, and viscera). These neurons
are called wide-dynamic-range (WDR) neurons. WDR
neurons receive input from Aβ and Aδ fibers as well as
from C fibers, either directly on their dendrites or indir-
ectly via excitatory interneurons that themselves receive
input from peripheral C fibers [38]. Neurons in lamina
VI receive input from nociceptors that mediate “fast
pain” activating ascending pathways that will lead to the
perception of pain as well as motor neurons involved in
the withdrawal reflex (the automatic withdrawal of an
extremity from a painful stimulus) [59].
During exposure to injury and subsequent activation
of peripheral stimuli, the central terminals of these
spinal cord nociceptors release a number of neurotrans-
mitters (e.g., glutamate, substance P, brain-derived
neurotrophic factor (BDNF), and calcitonin gene-related
peptide (CGRP)), which bind to receptors of postsynap-
tic neurons in the dorsal horn spinal cord’s lamina I.
When the exposure is brief and not caused by any per-
ipheral damage, the N-methyl D-aspartate (NMDA) sub-
type of the glutamate receptor is not activated. However,
when a repetitive and/or high-frequency stimulation of
C-fibers occurs, it is likely that the release of glutamate
and other substances leads to a prolonged, slow
depolarization of the neuron, and subsequent removal of
the NMDA block. When the NMDA receptor becomes
unblocked, a large influx of calcium ions (Ca2+) isoximately the level of the seventh cervical vertebra (C7) with
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cell, Ca2+ promotes transcriptional changes that subse-
quently contribute to the maintenance of nerve
sensitization [34].
In an attempt to prevent development of this
sensitization, which prolongs pain, ICU clinicians can
consider use of dual pharmacological therapies in certain
situations. For instance, mechanically ventilated patients
with Guillain-Barré syndrome and neuropathic pain can
receive superior pain relief from opioids plus oral gaba-
pentin or carbamazepine, which are both categorized as
antiepileptic and antihyperalgesic drugs compared with
the use of opioids alone [60,61]. In fact, gabapentin may
exert a selective effect on the nociceptive process
involved in central neuronal sensitization, which is the
rationale for its use in the treatment of acute postopera-
tive pain [62]. In addition, ketamine is an NMDA-
receptor antagonist that has been demonstrated to
prevent hyperalgesia in postoperative major abdominal
surgery patients [63]. The effectiveness of ketamine for
ICU patients requires further study.
Changes that occur to nerve synapses in dorsal horn
neurons as a result of stimulation that goes unblocked
are frequently compared with long-term potentiation
(LTP). LTP is a process that occurs in the cortex and
leads to the formation of long-term memory through
changes in synaptic plasticity [38]. The major synaptic
alteration that contributes to central sensitization and
ongoing pain is when increased activity in one set of
synapses results in the facilitation of the activity in an-
other set of synapses [34]. Long-term potentiation is
responsible for the major sensory manifestations asso-
ciated with central sensitization. One manifestation is
allodynia, which is when a person experiences pain in
a localized area that is not due to a painful stimulus
but, rather, a nonpainful stimulus, such as touch. A
second manifestation is called secondary hyperalgesia,
which is an increase in pain sensitivity in noninjured
areas beyond the area of primary injury [36]. It is
likely that the phenomenon of central sensitization
observed in pathologic clinical states includes both of
the above processes [34,64,65]. If this is the case,
avoiding LTP through analgesic control of acute pain
is an important goal.
Changes in inhibitory control at the level of the spinal
cord
When a nociceptive signal from the periphery reaches
the spinal cord, it is relayed to projection neurons,
which carry the signal along ascending pathways in the
spinal cord white matter to higher centers in the brain.
At the same time, inhibitory interneurons interact with
the terminals of primary nociceptors or projection neu-
rons to maintain the orderly processing of sensoryinformation [30,66]. The inhibitory function of inter-
neurons in the spinal cord is mediated by the release of
inhibitory neurotransmitters, such as γ-aminobutyric
acid (GABA) and glycine. Persistent nociceptive stimula-
tion caused by inflammation and/or neuropathy can
affect neurotransmission at this level in three ways: 1) by
decreasing the number of sites that release GABA and
glycine; 2) by decreasing the number of receptors to
which they bind; and 3) by increasing the speed by
which the inhibitory neurotransmitters are removed
from the synaptic cleft [67,68]. Thus, the disrupted func-
tion of interneurons due to loss of inhibitory control and
increased stimulation could contribute to the cascade of
events that lead to persistent chronic pain. Opioids, with
mu-receptors in the spinal cord, can help to maintain an
inhibitory effect. Indeed, opioids are the most frequently
used analgesics in ICUs, and IV opioids, such as fen-
tanyl, hydromorphone, and remifentanil, can be consid-
ered the first-line drug class of choice to treat
nonneuropathic pain in critically ill patients [69]. How-
ever, follow-up of these patients is required for the early
recognition of “opioid-induced hyperalgesia,” a paradox-
ical hyperalgesic state induced after the administration
or abrupt cessation of high opioid doses. Studies of
patients with chronic pain receiving opioid therapy as
well as chronic users of methadone support enhanced
pain perception during laboratory pain tests [37]. Never-
theless, due to the experimental setting of these studies
and the lack of evidence in the ICU setting, further re-
search is necessary to determine the presence of opioid-
induced hyperalgesia in ICU patients.
Changes in descending modulation
Under normal circumstances, dorsal horn spinal cord
neurons as well as the central terminals of primary affer-
ent fibers receive additional inhibitory input from fibers
that descend from supraspinal structures such as the cor-
tex, midbrain, and brain stem to the spinal cord [30,70-
72]. For example, fibers that descend from a midbrain
structure called the periaqueductal grey (PAG) (Figure 2)
activate serotoninergic neurons in the rostroventral me-
dulla (RVM) or noradrenergic neurons in the reticular
formation in the pons. When these descending inhibitory
neurons reach the spinal cord, they release serotonin and
noradrenaline. These substances act directly or indirectly
through other inhibitory interneurons to inhibit the re-
lease of noxious transmitters from primary afferent fibers
or to inhibit the activation of spinal cord neurons that
project a noxious stimulus to the brain [30]. Tramadol
has been recommended for consideration for mild pain,
because it is both a mu-receptor agonist and a serotonin
and noradrenaline reuptake inhibitor [69]. Inhibition of
reuptake inhibitors serotonin and noradrenaline main-
tains their prevention of nociceptive transmission.
Figure 2 Cerebral structures involved in the descending modulation of nociceptive information. Amyg, amygdala; CX, cortex; DRG, dorsal
root ganglion; DRT, dorsoreticular nucleus; Hypothal, hypothalamus; NA, noradrenaline; NTS, nucleus tractus solitarius; PAF, primary afferent fibre;
PBN, parabrachial nucleus; PAG, periaqueductal grey; Perikarya 5-HT, serotonergic perikarya; PN, projection neurones; RVM, rostroventral medulla
[30] (permission granted).
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dopamine, norepinephrine, and serotonin reuptake and,
thus, prevents nociceptive transmission. Its effectiveness
on moderate pain in a sample of 59 ICU patients has
been demonstrated, although some patients experienced
an increase in heart rate and decrease in mean arterial
pressure [73].
Of note, the RVM in the medulla also is an important
relay station for descending facilitatory influences on
nociceptive spinal transmission [74,75]. More specific-
ally, sustained ascending nociceptive input can activate
descending pain facilitatory systems from the rostroven-
tromedial medulla (RVM) through the release of prono-
ciceptive excitatory neurotransmitters. Thus, persistenceof pain for long periods could potentially lead to more
pain due to top-down effects on the spinal cord, another
reason for treating pain as aggressively as possible in
ICU patients.
Immune to nervous system interactions in the CNS and
pain facilitation
The “sickness response” is described as the constellation
of fever, increased sleep, decreased activity, and pain fa-
cilitation (i.e., sickness-induced hyperalgesia) [76]. Spinal
cord immune (i.e., glia) cells have been shown to partici-
pate in pain enhancement as part of the adaptive sickness
response; thus, they could be involved in pathological
pain states. Studies using animal models of inflammation,
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cord injury have shown that trauma or injury to periph-
eral nerves leads to activation of these immune cells in
the CNS [77-84].
Glia cells are numerous within the CNS, and recent
evidence suggests that neurons and glia cells constitute a
very important unit in the CNS [85]. Proinflammatory
cytokines released in the periphery transmit signals
through the blood–brain barrier to central structures
where they can activate nociceptive neurons [86]. Fur-
thermore, immune activation in the periphery can be
transferred by way of the vagus and glossopharyngeal
nerves [87,88]. These two nerves relay information dir-
ectly to the nucleus of the solitary tract, or NTS (nu-
cleus tractus solitarii) and ventromedial medulla rather
than passing through the spinal cord. These central
structures can activate nociceptive neurons of the
brainstem and give rise to the final branch of the
sickness-induced hyperalgesia pathway, which consists
of descending facilitatory fibers that target glia cells in
the spinal cord. Activation of glia cells leads to the re-
lease of proinflammatory cytokines within the CNS,
which bind to membrane receptors expressed by pain-
responsive dorsal horn neurons, increasing their excit-
ability [89-91]. Finally, one set of activated glial cells can
activate another set of glial cells, which augmentsFigure 3 Supraspinal areas involved in the modulation of pain. ACC, a
motor cortex; MDvc, ventrocaudal part of the medial thalamic dorsal nucle
dorsolateral pons; PCC, posterior cingulate cortex; PPC, posterior parietal co
cortical areas, respectively; SMA, supplementary motor area; VMpo, ventrom
ventroposterior lateral thalamic nucleus[95] (permission granted).nociceptive activation. In short, there is a positive feed-
back mechanism that intensifies and perpetuates pain.
Glial cells become activated during both acute inflam-
mation [92,93] and peripheral nerve damage, which can
lead to the development of neuropathic pain [94].
Central sensitization in brain areas
The perception of pain during both acute injury and in
chronic pain states undergoes substantial processing at
supraspinal levels (Figure 3) and involves many brain
areas. A number of nociceptive pathways project from
the spinal cord dorsal horn directly to brainstem and lim-
bic system areas. These pathways directly activate brain
structures involved in rudimentary emotional responses
to pain, such as autonomic nervous system (ANS) activa-
tion, escape, motor responses, arousal, and fear, which
require a minimum amount of cognition [95].
A major pathway through which nociceptive input
reaches the brain is the lateral spinothalamic tract. This
tract projects from the spinal cord to the thalamus and
from there to limbic cortical areas, such as the amygdala,
the anterior cingulate cortex (ACC), and insular cortex
(IC or insula). Another component of the spinothalamic
tract projects to somatosensory nuclei of the thalamus,
which relays nociceptive information to somatosensory
(S-1 and S-2) cortices [96]. This pathway is implicated innterior cingulate cortex; AMYG, amygdala; HT, hypothalamus; M1,
us; PAG, periaqueductal grey; PB, parabrachial nucleus of the
mplex; PF, prefrontal cortex; S1, S2, first and second somatosensory
edial part of the posterior thalamic nuclear complex; VPL,
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sations [95]. S1 cortex is generally associated with
sensory-discriminative aspects of pain, such as pain in-
tensity and location [97]; S2 cortex likely has additional
affective/cognitive functions.
There is a large matrix of pathways and brain areas that
work together to influence the pain experience. Some
neuronal pathways from S-1/S-2 cortices extend to pos-
terior parietal cortical areas (PPC) and IC, and from IC
to ACC, the amygdala, and hippocampus [98]. The IC
and ACC are important for affective-motivational and
certain cognitive aspects of pain, including attention, an-
ticipation, and evaluation [99-101]. Posterior parietal cor-
tical areas (PPC) integrate somatosensory input with
other sensory modalities, such as learning and memory
[98,102]. Thus, pain is a whole brain experience.
The convergence of pain pathways that occurs in the
brain provides support for a mechanism whereby mul-
tiple neural sources, including the limbic system, con-
tribute to pain affect; i.e., the emotional component of
pain. Convergence of neural pathways at the level of the
limbic system would be consistent with a mechanism in
which somatic perceptual and cognitive features of pain
would be integrated with attentional and emotion
mechanisms. Thus, the limbic system may have a com-
plex pivotal role in interrelating (facilitating or inhibit-
ing) attentional and evaluative functions with that of
establishing response priorities [102,103].
Sensory and affective dimensions of pain were, until
recently, believed to be the result of neural processing in
separate but parallel neuronal pathways and brain cen-
ters. A more current view proposes that the sensory and
affective experience of pain is the result of processing
that occurs in both serial and parallel ways [95]. That is,
regions of the brain involved in somatosensory proces-
sing also are important for the processing of the affective
dimension of pain. This knowledge could be particularly
useful to explore the transition from acute to chronic
pain,because the neurobiological dysregulation, mani-
fested at various levels of human functioning (e.g., be-
havioral, affective, sensory), could open a window on the
sequence of events that leads to the establishment of
chronic pain. If pain persists over a long period of time,
response priorities might change. Pain unpleasantness
endured over time engages prefrontal cortical areas
involved in reflection and rumination over the future
implications of a persistent pain condition [95]. These
reflections usually involve perceived interference with
one’s body, fear for loss of regular activity, and possible
difficulties with enduring pain over time; i.e., after dis-
charge from an ICU [17-19]. In fact, patients with
chronic pain are known to have higher postoperative
pain scores and a longer time to pain resolution after
surgery. Thus, identifying and treating their painaggressively after surgery could positively impact their
long-term pain state [104].
The prefrontal cortex (PFC)
The prefrontal cortex plays an important role in higher
order cognitive functions, such as planning, decision-
making, reward expectancy, avoidance of risky choices,
and goal-directed behaviors, in both animals and
humans [105]. It receives major input from limbic
structures, such as the amygdala, and is considered an
important area for value-based decision-making
[106,107]. Although limbic structures, such as amyg-
dala, ACC, and insula, appear to be important to effect
cognitive and emotional factors of pain, they them-
selves seem to be governed by the prefrontal cortex
[108]. Consistent with these observations, the brain
area most frequently activated in chronic pain patients
is the prefrontal cortex [109]. It is currently believed
that, in normal situations, the prefrontal cortex and a
network of other interconnected neural structures
exert an inhibitory influence on subcortical activation
associated with ANS activation and escape behaviors
[110]. For example, when a threatening stimulus, such
as perceived pain, alarms the subcortical network, the
prefrontal cortex diminishes the inhibitory control to
allow for sympathetic system activation and escape
behaviors. These responses and behaviors may help to
account for increases in heart rate and blood pressure
and facial expressions observed by ICU clinicians dur-
ing a patient’s pain experience. However, vital signs
cannot be used alone to determine whether pain is
present, because they are insensitive measures of pain
[111,112].
In the case of excessive activation of this inhibitory
network in the prefrontal cortex and in other intercon-
nected neural structures activated in the context of per-
sistent pain, the system might become dysregulated and
even disrupted. Such a neurophysiological state could
manifest itself as attentional, affective, and/or autonomic
dysregulation [110]. In fact, sometimes patients with
chronic pain are challenged by affective disorders (i.e.,
depression, anxiety), exhibit avoidance fears and
responses, and develop behaviors that do not have any
obvious adaptive character [113]. Thus, effectively man-
aging acute pain in ICU patients may help to prevent
the development of affective disorders that often accom-
pany chronic pain.
Conclusions
Long-term potentiation of synaptic responses in combin-
ation with disinhibition/facilitation of descending modu-
latory endogenous pain circuits and the immune system’s
activation seem to be critical in the development and
maintenance of conditions of central sensitization and
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the level of the spinal cord. Interestingly, similar changes
are currently being observed as involving several brain
areas associated with sensory perception, transmission,
modulation, and memory of pain [114]. At the same
time, altered emotional and cognitive processing is con-
sidered to be an important contributor to the excessive
suffering that is a hallmark of chronic pain conditions
[115]. Because the pain experience comprises both sen-
sory and emotional components, as presented earlier in
the definition of pain by IASP [20], some theorize that
physiological alterations that are allowed to persist may
be associated with augmentation in the perceptual,
affective, and/or motivational components of the pain
experience [95,109,113].
Although evidence about transition from acute to
chronic pain is new and still evolving and observations
are mainly derived from experiments under controlled
laboratory settings, this evidence is creating new areas
for exploration. Of particular concern is the need to bet-
ter understand physiological modifications that may
occur during the transition of a patient from acute to
chronic pain and to prevent this transition as much as
possible. Ultimately, the goal in critical care is to appre-
ciate the potential for this transition and attempt to pre-
empt it by aggressive use of therapeutic interventions for
pain. In addition, when an ICU patient is recognized as
having chronic pain along with their acute condition,
clinicians can appreciate the complexity of this condition
and use interventions that move toward targeting neuro-
pathic pain mechanisms and/or prevention of opioid-
induced hyperalgesia [10,37]. Future basic and clinical
research is warranted that tests interventions that could
be used to modulate both the somatic and the affective
dimension of the acute pain experience and potentially
prevent the transition from acute-to-chronic pain.
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